1H- and 31P-myocardial magnetic resonance spectroscopy in non-obstructive hypertrophic cardiomyopathy patients and competitive athletes
- 212 Downloads
The clinical differentiation between athlete’s heart and mild forms of non-obstructive hypertrophic cardiomyopathy (HCM) is crucial. We hypothesized that differences do exist between the myocardial metabolism of patients with non-obstructive HCM and competitive athletes (CAs). Our aim was to evaluate myocardial metabolism with 31P-MRS and 1H-MRS in HCM patients and CAs.
Materials and methods
After Ethics Committee approval, 15 CAs and 7 HCM patients were prospectively enrolled. They underwent a 1.5-T cardiac MR including electrocardiographically triggered cine images, single-voxel 1H-MRS and multivoxel 31P-MRS. 1H-MRS was performed after imaging using standard coil with the patient in the supine position; thereafter, 31P-MRS was performed using a dedicated coil, in the prone position. Data were reported as median and interquartile range. Mann–Whitney U test was used.
In CAs, left ventricular mass index was 72 (66–83) g/m2, septal thickness 10 (10–11) mm, end diastolic volume index 95 (85–102) ml/m2, end systolic volume index 30 (28–32) ml/m2 and ejection fraction 68% (65–69%); in HCM patients, 81 (76–111) g/m2 (P = 0.052), 18 (15–21) mm (P = 0.003), 73 (58–76) ml/m2 (P = 0.029), 20 (16–34) ml/m2 (P = 0.274) and 68% (55–73%) (P = 1.000), respectively. At 1H-MRS, total lipids were 35 (0–183) arbitrary units (au) for CA and 763 (155–1994) au for HCM patients (P = 0.046). At 31P-MRS, PCr/γATP was 5 (4–6) au for CA and 4 (2–5) au for HCM patients (P = 0.230). Examination time was 20 min for imaging only, 5 min for 1H-MRS and 15 min for 31P-MRS.
We observed a significant increase of myocardial lipids, but a preserved PCr/γATP ratio in the metabolism of HCM patients compared with competitive CAs.
KeywordsMyocardial metabolism Athlete’s heart Hypertrophic cardiomyopathy Magnetic resonance spectroscopy
This research received no specific grants from any funding agency in the public, commercial or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
F Secchi and G. Di Leo have been sponsored to congresses by Bracco Imaging SpA (Milan, Italy). F. Sardanelli is on the speaker’s bureau for Bracco Imaging SpA (Milan, Italy) and received research grants from Bayer Healthcare (Berlin, Germany).
This article does not contain any studies with human participants or animals performed by any of the authors.
- 34.Nelson MD, Victor RG, Szczepaniak EW et al (2013) Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am J Cardiol 112:1019–1024. doi: 10.1016/j.amjcard.2013.05.036 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Utz W, Engeli S, Haufe S, Kast P, Hermsdorf M, Wiesner S, Pofahl M, Traber J, Luft FC, Boschmann M, Schulz-Menger J, Jordan J (2011) Myocardial steatosis, cardiac remodelling and fitness in insulin-sensitive and insulin-resistant obesewomen. Heart 97(19):1585–1589Google Scholar
- 36.Schrauwen-Hinderling VB, Meex RCR, Hesselink MKC et al (2011) Cardiac lipid content is unresponsive to a physical activity training intervention in type 2 diabetic patients, despite improved ejection fraction. Cardiovasc Diabetol 10:47. doi: 10.1186/1475-2840-10-47 CrossRefPubMedPubMedCentralGoogle Scholar